~~<i id='8E66925136'><strike id='8E66925136'><tt id='8E66925136'><pre id='8E66925136'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：leisure time 2025-09-30 12:00:42 Page View：5747

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What will Novo Nordisk's VC do with its influx of cash?
Next article： ChatGPT in medicine: STAT answers readers' burning questions

explore

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Doctors are clamoring for more clarity on Paxlovid prescribing

ApatientwithpillsofPaxlovid.SixmonthsaftertheemergencyuseauthorizationofPaxlovidforhigh-riskCovidpat

George Santos makes 1st court appearance after pleading not guilty to 13 counts

1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

Sage considers ways to reduce costs following FDA rejection

DrewAngerer/GettyImagesSageTherapeuticssaidMondaythatitmayneedtoreducecosts,includingthroughemployee